🧪 OpenAI buys Orchestra Bio to handle the paperwork side of drug development
OpenAI is folding the San Francisco startup's team and tech into Rosalind, its life sciences suite. Orchestra's platform coordinates the drug development process, so GPT-Rosalind gets a workflow layer on top of the biology and chemistry reasoning. Financial terms weren't disclosed.
OpenAI is folding the San Francisco startup's team and tech into Rosalind, its life sciences suite. Orchestra's platform coordinates the drug development process, so GPT-Rosalind gets a workflow layer on top of the biology and chemistry reasoning. Financial terms weren't disclosed.
OpenAI
OpenAI acquires Orchestra Bio
OpenAI is acquiring Orchestra Bio to bring AI-powered operations to life sciences R&D, helping biopharma teams accelerate drug development and advance new treatments.
🤖 Kimi K3.1 Pro hits 55 on Artificial Analysis and sits on the Pareto line
Artificial Analysis puts the open-weight model on the cost-vs-score frontier, so nothing cheaper beats it at that level. But on its Omniscience eval, K3.1 trails the frontier by roughly 6 months, and DeepSeek 4.1 Flash trails by about 12.
Artificial Analysis puts the open-weight model on the cost-vs-score frontier, so nothing cheaper beats it at that level. But on its Omniscience eval, K3.1 trails the frontier by roughly 6 months, and DeepSeek 4.1 Flash trails by about 12.
artificialanalysis.ai
Kimi K3.1 Pro - Intelligence, Performance & Price Analysis | Artificial Analysis
Analysis of Kimi's Kimi K3.1 Pro and comparison to other AI models across key metrics including quality, price, performance (tokens per second & time to first token), context window & more.